Global Liposomes Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Stealth Liposomes, Conventional Liposomes, Cationic Liposomes, and Others), By Applications (Cosmetics, Drug Delivery, Food and Beverages, Gene Delivery, and Others), By End-User (Cosmetics Industry, Pharmaceutical and Biotechnology Companies, Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Liposomes Market Insights Forecasts to 2033

• The Global Liposomes Market Size Was Estimated at USD 7.01 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 5.94 % from 2023 to 2033
• The Worldwide Liposomes Market Size is Expected to reach USD 12.48 Billion By 2033
• Asia Pacific is Predicted to Grow at the Fastest CAGR throughout the Projection Period

The Global Liposomes Market Size is Predicted to Exceed USD 12.48 Billion by 2033, Growing at a CAGR of 5.94% from 2023 to 2033. The liposomes market growth is attributed to the increasing incidence of chronic diseases, the growing trend of nanotechnology and novel drug delivery systems, technological advancements in liposomal formulations, government financial support, and the rising proportion of molecular research findings.

Market Overview

The liposomes market deals with the formulation and application of liposomes for the encapsulation of active pharmaceutical ingredients to improve the stability and therapeutic efficacy of the medications that are used in the management of acute and chronic diseases. Liposomes are spherical artificial membranes with phospholipid bilayers, known for their membrane-like properties, biocompatibility, stability, and selectivity. They are self-assembled colloidal particles that can deliver both hydrophobic and hydrophilic ingredients.

Liposomes are prepared by encapsulating the API in a phospholipid bilayer, and traditional methods for liposome preparation include thin-film hydration, membrane extrusion, and reverse-phase evaporation vesicles. Liposomes are promising drug delivery systems approved by the FDA for disease treatment and diagnostic applications. They are primarily made from phospholipids and can be administered via various routes. Cholesterol is essential in liposomes to modulate membrane permeability and improve stability. Liposomal formulations may contain polymers and membrane proteins to prolong circulation and enhance drug effectiveness. The formulation methods of the liposomes are the thin film hydration method, reverse phase evaporation method, solvent injections method, detergent removal method, supercritical fluidic method, etc. The marketed products of liposomal formulations are DaunoXome (anti-cancer), Exparel (analgesic), Fungisome (Amphotericin B), etc.

The rising prevalence of chronic diseases such as cardiovascular, cancer, diabetes, etc., and aesthetic living of patients escalates the need for innovative treatment approaches such as novel drug delivery such as liposomal-based treatment which results in the growth of the liposomes market. For instance, the data provided by the World Health Organization states that cancer is a significant global health concern, causing 1 in 6 deaths and affecting nearly every household. In 2022, 20 million new cases and 9.7 million deaths occurred, with the burden expected to increase by 77% by 2050. A major concern for medical professionals and researchers is cancer, a condition marked by abnormally rapid growth of cells. Complications are further raised by the medicinal drugs' short half-lives and quantity. There is a need for innovation in anticancer medication qualities since tumor cells are developing more resistant to traditional therapies like chemotherapy and radiation. Liposomes can retain medications with a variety of physical and chemical properties, making them an excellent option for drug delivery and cancer treatment in nanomedicine. Their pharmacological virtues and the efficacy of anticancer medications are enhanced by their high degree of flexibility and chemical modification potential through the conjugation of polymers, ligands, and molecules. Liposomes have the potential to improve anti-malignant cell therapies' sensitivity, specificity, and endurance, which has important implications for applications in nanomedicine.

Several government initiatives such as providing research funding for research studies drive the market growth. For example, the National Nanotechnology Initiative (NNI) is an R&D initiative launched by the United States Government involving over thirty federal departments, independent agencies, and commissions. It aims to understand and control matter at the nanoscale, leading to technological and industry revolutions benefiting society. The NNI enhances interagency coordination, supports a shared infrastructure, and establishes shared goals, priorities, and strategies. The National Nanotechnology Coordination Office (NNCO) conducts public engagement and provides technical and administrative support to the NSET Subcommittee and the interagency nanotechnology community. NNCO activities include convening the community, sharing resources and opportunities, engaging with the public, and exciting students about nanotechnology. The NNCO also has an Industry and Regional Liaison to monitor and support the nanotechnology business community.

Report Coverage

This research report categorizes the global liposomes market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global liposomes market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global liposomes market.

Driving Factors:

Innovations in the liposomes:

Liposomal formulations in clinical trials offer significant benefits to various patients. Techniques like electroformation, hydration, and extrusion are widely used for various applications. Electroformation involves forming a lipid layer on an electrode, followed by applying an electric field to peel off the lipids for self-assembly into vesicles. Microfluidic technologies provide high control over the process and manufacture, overcoming reproducibility issues. Microfluidics involves precise control of fluids in geometrically constrained volumes, reducing reaction volumes and increasing throughput and analytical performance. CRISPR technology has revolutionized molecular biology as a genomic editing tool for treating genetic diseases and cancers. CRISPR/Cas9 therapeutics target and downregulate genes of interest. Nitric oxide (NO) has anti-inflammatory effects, lowered plaque formation, and inhibition of platelet aggregation and adhesion. Gas-containing liposomes are prepared by combining liposomes with gas under pressure and freezing-thawing the gas-liposome dispersion.

Growing usage of liposomes as a drug delivery system:

Liposomes are versatile drug vesicles with superior properties compared to traditional delivery systems. They offer site-targeting, controlled release, drug protection, superior therapeutic effects, and lower toxic side effects. Liposomes have been approved and used in clinics in food and cosmetics. They also protect encapsulated substances from degradation, extend drug half-life, control drug molecule release, and have excellent biocompatibility and safety. Liposomes can selectively deliver their payload to the diseased site, reducing systemic side effects, increasing the maximum-tolerated dose, and improving therapeutic benefits. Liposomes resemble the plasma membrane of the cell and are considered safe based on clinical studies. They are suitable for the lipophilic and hydrophilic drugs. Even gasses such as nitric oxide can be encapsulated into the liposomes to treat pulmonary hypertension. Therefore, the growing use of liposomes as drug-delivery systems in the management of diseases fuels the market expansion.

Restraining Factors

The complex formulation methods of liposomes, increased costs of its formulation methods and raw material, stringent regulatory guidelines, shorter shelf life, and availability of other novel drug delivery systems such as niosomes, and exosomes may hinder the growth of the market.

Market Segmentation

The global liposomes market share is classified into product type, applications, and end-user.

• The conventional liposomes segment dominated the liposomes market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global liposomes market is categorized into stealth liposomes, conventional liposomes, cationic liposomes, and others. Among these, the conventional liposomes segment dominated the liposomes market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is owing to non-toxic, enhanced pharmacokinetic effects, non-immunogenic, greater efficacy, and safety, improved stability of the drug molecules, efficient encapsulation, improved drug delivery, and ability to carry hydrophilic and lipophilic drugs.

• The drug delivery segment accounted for the largest market share of 85.27% in 2023 and is anticipated to grow at a significant CAGR throughout the projected timeframe.

Based on the applications, the global liposomes market is categorized into cosmetics, drug delivery, food and beverages, gene delivery, and others. Among these, the drug delivery segment accounted for the largest market share of 85.27% in 2023 and is anticipated to grow at a significant CAGR throughout the projected timeframe. The segment growth is attributed to the targeted drug delivery, minimizes the risk of side effects, and adaptability, improves the stability of the therapeutic drug, and improves the treatment intensity, highly effective for cancerous drugs to enhance the therapeutic activity of particular drug.

• The pharmaceutical and biotechnology companies segment held a significant share in 2023 and is predicted to grow at a significant CAGR throughout the estimated period.

Based on the end-user, the global liposomes market is categorized as the cosmetics industry, pharmaceutical and biotechnology companies, research institutes, and others. Among these, the pharmaceutical and biotechnology companies segment held a significant share in 2023 and is predicted to grow at a significant CAGR throughout the estimated period. The sector is expanding owing to the escalating need for novel drug delivery systems, increasing chronic diseases and complex treatment results in the increasing demand for liposomal formulations, rising molecular studies, and a growing proportion of clinical trials.

Regional Segment Analysis of the Global Liposomes Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global liposomes market over the predicted timeframe.

North America is anticipated to hold the largest share of the global liposomes market over the predicted timeframe. An expanding pharmaceutical sector and a significant volume of research and development activities are the main drivers of this. Innovative medication delivery methods like liposomes are in high demand due to the region's sophisticated healthcare infrastructure and the rising incidence of chronic illnesses like cancer. The United States, in particular, has made large investments in biotechnology and nanotechnology research, which has contributed significantly to the market's growth. New developments in material sciences and nanotechnology have rendered it possible to develop liposomal compositions that have grown more specialized and effective. Apart from the pharmaceutical sector, liposomes are additionally growing popular in the food and beverage industry for their ability to supply nutrients and prolong shelf life which drives the market growth in North America.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is driven by the growing pharmaceutical and cosmetics companies as well as higher expenses in healthcare. The need for efficient and focused treatments is rising in nations like China and India as a result of expanding middle-class communities and better access to healthcare. The adoption of liposomal formulations is further supported by the region's growing cosmetics industry, with an emphasis on innovation and the distinctiveness of goods.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global liposomes market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Virpax Pharmaceuticals
• Gilead Sciences, Inc.
• Azaya Therapeutics
• Nanovex Biotechnologies SL
• Avanti Polar Lipids Inc.
• Ipsen Biopharmaceuticals, Inc.
• S.G. Biopharma Pvt. Ltd.
• Taiwan Liposome Company Ltd.
• FujiFilm Holdings Corporation
• Synpac Kingdom Pharmaceutical Co., Ltd.
• Novartis AG
• Pacira BioSciences, Inc.
• Encapsula Nano Sciences
• Precision NanoSystems Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2025, Innocan Pharma Corporation was granted a patent in India for its synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), a prolonged-release pharmaceutical formulation that uses liposomes to encapsulate cannabinoids. The patent protects Innocan's LPT-CBD, which has received positive feedback from the FDA for its potential use as a non-opioid alternative for chronic pain management.

• In October 2024, Lipella Pharmaceuticals received a US Patent and Trademark Office (USPTO) notice of allowance for its proprietary liposomal drug delivery platform. The patent application, titled "Delivery of Agents Using Metastable Liposomes," covers Lipella's platform technology for delivering therapeutic agents via liposome-based vehicles. The patent allows claims for Lipella's method for using metastable liposomes to deliver various therapeutic agents, including its lead assets, LP-10 and LP-310. This technology improves the safety and efficacy of treatments in oncology, cancer survivorship, and immunotherapy.

• In August 2024, Lupin launched Doxorubicin Hydrochloride Liposome Injections 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the US, following approval from the US FDA for its ANDA by Lupin's alliance partner, ForDoz Pharma Corporation, USA. This generic equivalent of Doxil® (Liposomal) is used for treating Ovarian Cancer, AIDS-related Kaposi's Sarcoma, and Multiple Myeloma.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global liposomes market based on the below-mentioned segments:

Global Liposomes Market, By Product Type

• Stealth Liposomes
• Conventional Liposomes
• Cationic Liposomes
• Others

Global Liposomes Market, By Applications

• Cosmetics
• Drug Delivery
• Food and Beverages
• Gene Delivery
• Others

Global Liposomes Market, By End-User

• Cosmetics Industry
• Pharmaceutical and Biotechnology Companies
• Research Institutes
• Others

Global Liposomes Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa